$0.06
15.0%
Downside
Day's Volatility :15.0%
Upside
0.0%
0.0%
Downside
52 Weeks Volatility :99.42%
Upside
99.42%
Period | Biolase Inc | Index (Russel 2000) |
---|---|---|
3 Months | -58.62% | 0.0% |
6 Months | -57.14% | 0.0% |
1 Year | -98.1% | 0.0% |
3 Years | -100.0% | -22.3% |
Market Capitalization | 2.2M |
Book Value | - $0.13 |
Earnings Per Share (EPS) | 16.18 |
PE Ratio | 0.0 |
PEG Ratio | -0.22 |
Wall Street Target Price | 1.2 |
Profit Margin | -41.65% |
Operating Margin TTM | -27.87% |
Return On Assets TTM | -27.96% |
Return On Equity TTM | -736.26% |
Revenue TTM | 46.1M |
Revenue Per Share TTM | 3.32 |
Quarterly Revenue Growth YOY | -19.1% |
Gross Profit TTM | 16.5M |
EBITDA | -13.2M |
Diluted Eps TTM | 16.18 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.44 |
EPS Estimate Next Year | -0.09 |
EPS Estimate Current Quarter | -0.07 |
EPS Estimate Next Quarter | -0.06 |
What analysts predicted
Upside of 3150.0%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 46.2M | ↓ 1.64% |
Net Income | -21.5M | ↑ 27.68% |
Net Profit Margin | -46.62% | ↓ 10.71% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 37.8M | ↓ 18.1% |
Net Income | -17.9M | ↓ 17.02% |
Net Profit Margin | -47.24% | ↓ 0.62% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 22.8M | ↓ 39.73% |
Net Income | -16.8M | ↓ 5.75% |
Net Profit Margin | -73.88% | ↓ 26.64% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 39.2M | ↑ 72.03% |
Net Income | -16.2M | ↓ 3.99% |
Net Profit Margin | -41.23% | ↑ 32.65% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 48.5M | ↑ 23.67% |
Net Income | -28.6M | ↑ 77.21% |
Net Profit Margin | -59.09% | ↓ 17.86% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 49.2M | ↑ 1.45% |
Net Income | -20.6M | ↓ 27.95% |
Net Profit Margin | -41.97% | ↑ 17.12% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 14.1M | ↑ 16.99% |
Net Income | -9.9M | ↑ 17.57% |
Net Profit Margin | -70.18% | ↓ 0.35% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.5M | ↓ 25.51% |
Net Income | -5.8M | ↓ 40.69% |
Net Profit Margin | -55.88% | ↑ 14.3% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 14.3M | ↑ 36.49% |
Net Income | -4.9M | ↓ 16.77% |
Net Profit Margin | -34.08% | ↑ 21.8% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.9M | ↓ 23.55% |
Net Income | -4.6M | ↓ 5.73% |
Net Profit Margin | -42.02% | ↓ 7.94% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 13.5M | ↑ 23.52% |
Net Income | -5.3M | ↑ 16.06% |
Net Profit Margin | -39.48% | ↑ 2.54% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 10.1M | ↓ 24.9% |
Net Income | -6.5M | ↑ 21.76% |
Net Profit Margin | -64.01% | ↓ 24.53% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 38.5M | ↓ 10.39% |
Total Liabilities | 27.4M | ↑ 99.85% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 31.8M | ↓ 17.31% |
Total Liabilities | 31.5M | ↑ 14.74% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 41.0M | ↑ 28.82% |
Total Liabilities | 31.0M | ↓ 1.5% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 55.3M | ↑ 34.76% |
Total Liabilities | 30.1M | ↓ 2.97% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 38.2M | ↓ 30.93% |
Total Liabilities | 33.3M | ↑ 10.71% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 35.1M | ↓ 8.08% |
Total Liabilities | 35.3M | ↑ 6.16% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 38.2M | ↓ 10.92% |
Total Liabilities | 33.3M | ↑ 14.79% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 41.9M | ↑ 9.84% |
Total Liabilities | 33.8M | ↑ 1.47% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 39.6M | ↓ 5.51% |
Total Liabilities | 32.3M | ↓ 4.42% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 38.7M | ↓ 2.24% |
Total Liabilities | 32.9M | ↑ 1.76% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 35.1M | ↓ 9.41% |
Total Liabilities | 35.3M | ↑ 7.57% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 34.4M | ↓ 2.13% |
Total Liabilities | 36.3M | ↑ 2.66% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.1M | ↓ 23.16% |
Investing Cash Flow | -522.0K | ↓ 30.12% |
Financing Cash Flow | 11.2M | ↓ 48.03% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.7M | ↓ 9.9% |
Investing Cash Flow | -207.0K | ↓ 60.34% |
Financing Cash Flow | 10.7M | ↓ 4.57% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -12.8M | ↑ 0.38% |
Investing Cash Flow | -96.0K | ↓ 53.62% |
Financing Cash Flow | 24.3M | ↑ 127.12% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.7M | ↑ 30.6% |
Investing Cash Flow | -707.0K | ↑ 636.46% |
Financing Cash Flow | 30.0M | ↑ 23.02% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.6M | ↓ 14.73% |
Investing Cash Flow | -471.0K | ↓ 82.41% |
Financing Cash Flow | -32.0K | ↓ 85.05% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.7M | ↑ 1.36% |
Investing Cash Flow | -357.0K | ↓ 24.2% |
Financing Cash Flow | 8.5M | ↓ 26715.62% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.6M | ↓ 37.04% |
Investing Cash Flow | -357.0K | ↑ 0.0% |
Financing Cash Flow | 4.3M | ↓ 49.79% |
Sell
Neutral
Buy
Biolase Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Biolase Inc | -8.09% | -57.14% | -98.1% | -100.0% | -100.0% |
![]() Stryker Corporation | 12.3% | 0.36% | 24.19% | 28.8% | 65.26% |
![]() Boston Scientific Corp. | 10.6% | 20.32% | 51.42% | 80.93% | 95.5% |
![]() Edwards Lifesciences Corp. | 9.4% | -28.78% | -12.2% | -45.23% | -7.73% |
![]() Abbott Laboratories | 3.57% | -5.84% | 13.1% | -11.32% | 35.19% |
![]() Medtronic Plc | 10.85% | 5.57% | 12.46% | -33.2% | -16.71% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Biolase Inc | NA | 0.0 | -0.22 | -0.44 | -7.36 | -0.28 | NA | -0.13 |
![]() Stryker Corporation | 39.84 | 39.84 | 2.64 | 12.0 | 0.19 | 0.07 | 0.01 | 51.86 |
![]() Boston Scientific Corp. | 66.34 | 66.34 | 2.01 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
![]() Edwards Lifesciences Corp. | 26.3 | 26.3 | 3.2 | 2.69 | 0.22 | 0.12 | NA | 12.35 |
![]() Abbott Laboratories | 35.92 | 35.92 | 4.16 | 4.66 | 0.14 | 0.06 | 0.02 | 22.6 |
![]() Medtronic Plc | 30.16 | 30.16 | 1.66 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Biolase Inc | Buy | $4.8M | -100.0% | NA | -41.65% |
![]() Stryker Corporation | Buy | $136.8B | 65.26% | 39.84 | 16.12% |
![]() Boston Scientific Corp. | Buy | $120.2B | 95.5% | 66.34 | 12.0% |
![]() Edwards Lifesciences Corp. | Buy | $40.2B | -7.73% | 26.3 | 23.74% |
![]() Abbott Laboratories | Buy | $198.1B | 35.19% | 35.92 | 13.65% |
![]() Medtronic Plc | Buy | $115.3B | -16.71% | 30.16 | 12.06% |
Insights on Biolase Inc.
Revenue is up for the last 2 quarters, 10.13M → 11.55M (in $), with an average increase of 12.3% per quarter
Netprofit is up for the last 2 quarters, -6.48M → -2.79M (in $), with an average increase of 131.8% per quarter
In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 149.5%
In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 180.9%
Virtu Financial LLC
Millennium Management LLC
HRT FINANCIAL LLC
XTX Topco Ltd
Royal Bank of Canada
Susquehanna International Group, LLP
biolase, inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment. biolase’s products are focused on better enabling clinicians to repair and restore patient’s dental conditions while reducing the pain, fear, and anxiety generally associated with dentistry. biolase is committed to elevating the standard of care in dentistry, while enabling clinicians to achieve better business returns.
Organization | Biolase Inc |
Employees | 157 |
CEO | Mr. John R. Beaver |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.06
+7.14%
Keyarch Acquisition Corp
$0.06
+7.14%
Connexa Sports Technologies Inc
$0.06
+7.14%
Us Value Etf
$0.06
+7.14%
First Wave Biopharma Inc
$0.06
+7.14%
Global X Msci Next Emerging
$0.06
+7.14%
Fat Projects Acquisition Corp
$0.06
+7.14%
Capital Link Global Fintech
$0.06
+7.14%
Applied Uv Inc
$0.06
+7.14%